Exploring the impact of mobile and migrant populations on mass drug administration coverage and effectiveness in Africa: A scoping review protocol
PLOS One · 29.05.2025 · 20 (5) · e0324949
DOI: 10.1371/journal.pone.0324949 ↗Kurz gefasst
Scoping Review in der Zeitschrift PLOS One, online erschienen am 29.05.2025. Verfasst von Moussa Sangare und 7 weiteren Autor:innen. Beteiligte Einrichtung: International Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali. Hauptthemen laut MEDLINE: Transients and Migrants, Mass Drug Administration, Neglected Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neglected tropical diseases (NTDs) affect populations in tropical regions, particularly low- and middle-income countries with limited economic and health resources. Mass drug administration (MDA) is a strategy for controlling and eliminating NTDs by treating entire at-risk populations to reduce parasite loads, interrupt transmission, and prevent reinfection. It is cost-effective, and promotes equity by reaching underserved communities. MDA is a critical approach to controlling and eliminating NTDs. Mobile populations in Africa such as nomadic groups and internally displaced persons, may lack access to MDA, which poses challenges to NTD elimination. This study aims to explore the influence of population mobility on the implementation, effectiveness, and sustainability of MDA in Africa. Materials and methods This scoping review adheres to the PRISMA extension for scoping reviews and Joanna Briggs Institute (JBI) methodology. PCC (Population, Concept, Context) serves as the foundation for the study. Relevant papers published after 2000 will be identified through a comprehensive search of Medline Ovid, Embase, Web of Science, and gray literature. Studies addressing challenges to MDA in Africa’s and related to mobile populations will be included. An Excel spreadsheet modified from the JBI will be used for data extraction and analysis.
Conclusion
The results of this review will shed light on how MDA coverage is affected by the phenomenon of mobile and migrant populations and what effective approaches, if any, have been used to address this problem and improve overall population access to MDA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- International Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
- Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada.
- Bruyère Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
- School of Epidemiology and Public Heath, University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada.
ORCID-Profile: Moussa Sangare
Zitieren
APA
Sangare, M., Coulibaly, Y. I., Ravichandran, P., Diabate, A. F., Duguay, C., Vlassoff, C., Kulkarni, M. A., & Krentel, A. (2025). Exploring the impact of mobile and migrant populations on mass drug administration coverage and effectiveness in Africa: A scoping review protocol. PLOS One, 20(5), e0324949. https://doi.org/10.1371/journal.pone.0324949
Vancouver
Sangare M, Coulibaly YI, Ravichandran P, Diabate AF, Duguay C, Vlassoff C, et al. Exploring the impact of mobile and migrant populations on mass drug administration coverage and effectiveness in Africa: A scoping review protocol. PLOS One. 2025;20(5):e0324949. doi:10.1371/journal.pone.0324949
BibTeX
@article{Sangare2025,
author = {Sangare, Moussa and Coulibaly, Yaya Ibrahim and Ravichandran, Prithi and Diabate, Abdoul Fatao and Duguay, Claudia and Vlassoff, Carol and Kulkarni, Manisha A and Krentel, Alison},
title = {Exploring the impact of mobile and migrant populations on mass drug administration coverage and effectiveness in Africa: A scoping review protocol},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {5},
pages = {e0324949},
doi = {10.1371/journal.pone.0324949}
}
EUVIMED